Startups
MyoPax uses its proprietary muscle stem cell technology to develop advanced regenerative therapies and fight the devastating consequences of muscle diseases.
MyoPax is a spin-off from Charité Universitätsmedizin and Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association.
MyoPax is a spin-off from Charité Universitätsmedizin and Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association.
Overview
Location
Denmark
Employees
1-10
Total raised
$1.3M
FAQ about MyoPax
How much funding has MyoPax raised?
MyoPax has raised $1.3M in total across 1 funding round.
Is MyoPax still active?
Yes, MyoPax is active; its latest activity on Parsers VC dates from Oct 20, 2026.